Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Oral X-82 (Vorolanib) in Wet AMD
NCT01674569Phase 2Completed
- Sponsor
- Tyrogenex
- Start
- Oct 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in neovascular age-related macular degeneration (NVAMD), sponsored by Tyrogenex. Started Oct 2012; status: completed.
02
Drugs
vorolanib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01674569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674569.